AAP
MIST icon

Arax Advisory Partners’s Milestone Pharmaceuticals MIST Stock Holding History

Arax Advisory Partners’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,591
Closed -$3.21K – 4128
2025
Q4 		$3.21K Buy
1,591
+514
+48% +$1.11K ﹤0.01% 3075
2025
Q3 		$2.15K Buy
+1,077
New +$1.89K ﹤0.01% 3098

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Arax Advisory Partners's MIST Position: Q1 2026 in Review

Arax Advisory Partners sold out of Milestone Pharmaceuticals (MIST) in Q1 2026, closing a stake of 1,591 shares — an estimated $3.21K sold.

Arax Advisory Partners first reported a position in MIST in Q3 2025 and held it in 2 quarters. The position peaked at $3.21K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Arax Advisory Partners reported no remaining Milestone Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 1,591 Milestone Pharmaceuticals shares in Q1 2026, an estimated $3.21K.
  • Arax Advisory Partners first reported a position in Milestone Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Arax Advisory Partners's Milestone Pharmaceuticals position peaked at $3.21K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.